Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

At the moment, the hottest GLP-1 treatment is Ozempic. Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 8 unusual trades. Delving into the details, we found 50% of ...

While the CagriSema program is far from Novo Nordisk's only candidate for treating obesity or diabetes, it's the only late-stage program that could be submitted for approval sometime in the latter ...

of Novo Nordisk "Site Odense" in Kroghs park in Odense, Denmark, on December 16, 2024. (Photo by Mads Claus Rasmussen / Ritzau Scanpix / AFP) / Denmark OUT (Photo by MADS CLAUS RASMUSSEN/Ritzau ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...